suspensaside: from fruit of Forsythia suspensa Vahl (Oleaceae); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Forsythia | genus | A plant genus of the family OLEACEAE. Members contain suspensaside.[MeSH] | Oleaceae | A plant family of the order Lamiales. The leaves are usually opposite and the flowers usually have four sepals, four petals, two stamens, and two fused carpels that form a single superior ovary.[MeSH] |
| Forsythia suspensa | species | [no description available] | Oleaceae | A plant family of the order Lamiales. The leaves are usually opposite and the flowers usually have four sepals, four petals, two stamens, and two fused carpels that form a single superior ovary.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 5281798 |
| MeSH ID | M0114344 |
| Synonym |
|---|
| 84213-44-5 |
| suspensaside |
| C10499 , |
| AC1NQZ3W , |
| [(2r,3s,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-hydroxyethoxy]-4,5-dihydroxy-2-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate |
| 3,4-trihydroxyphenethyl-o-rhamnopyranosyl-(1-6)-4-o-caffeoyl-glucopyranoside |
| beta-d-glucopyranoside, 2-(3,4-dihydroxyphenyl)-2-hydroxyethyl 6-o-(6-deoxy-alpha-l-mannopyranosyl)-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate)-, (e)- |
| [(2r,3s,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-hydroxy-ethoxy]-4,5-dihydroxy-2-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate |
| (r)-suspensaside |
| (s)-suspensaside |
| A903080 |
| b-d-glucopyranoside,2-(3,4-dihydroxyphenyl)-2-hydroxyethyl 6-o-(6-deoxy-a-l-mannopyranosyl)-,4-[(2e)-3-(3,4-dihydroxyphenyl)-2-propenoate] |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.27) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||